Allogene Therapeutics (ALLO) CFO Parker Sells $49K of Stock
Key Points
- CFO Geoffrey M. Parker sold 36,342 shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) at $1.34 each on October 21, 2026.
- The transaction lowered his personal holding to 1,045,877 shares, representing a 3.4% reduction in his stake.
- Citizens reiterated its market outperform rating with a $6.00 price target on August 17, 2026.
Since the trade, $ALLO is down 6.0% to date (from the $1.33 close on Oct 21, 2026).
Get Allogene Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $ALLO.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Allogene Therapeutics, Inc. alert may contain errors. Disclosures
Chief Financial Officer Geoffrey M. Parker sold 36,342 shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) on October 21, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the transaction took place at a price of $1.34 per share for a total value of $48,698.28.
ALLO
Allogene Therapeutics, Inc.
Inside Geoffrey M. Parker's Allogene Therapeutics Trade
The sale reduced Parker's direct stock ownership by 3.36%, leaving him with 1,045,877 shares of the biotechnology company. The transaction was executed at $1.34 per share on a day when the stock closed at $1.33. This sale was not executed under a pre-arranged Rule 10b5-1 trading plan.
Other Institutional Activity in Allogene Therapeutics
Large investors adjusted their positions in the company earlier in the year. Frazier Life Sciences Management, L.P. grew its holdings by 18,649,999 shares, ending with 22,446,668 shares worth about $28,058,335. Pfizer Inc held steady with 22,032,040 shares valued at about $27,540,050. TPG GP A, LLC maintained its stake at 18,716,306 shares worth about $23,395,382. Sio Capital Management, LLC grew its holdings by 6,661,716 shares, ending with 13,323,431 shares worth about $16,654,288. Primecap Management Company increased its position by 4,743,745 shares to end with 13,123,440 shares valued at about $16,404,300.
Allogene Therapeutics, Inc. Stock Down 6.0%
The stock recently traded around $1.25 as of October 23, 2026. On the day of the trade, the company's shares closed at $1.33.
Recent Earnings
The biotech firm reported trailing-twelve-month revenue of $4.64 million and negative earnings of $0.66 per share. The company has a return on equity of negative 42.4%. Investors will look toward the company's upcoming earnings release on November 5, 2026, for updates on its clinical pipeline and financial status.
Insider Buying and Selling at Allogene Therapeutics, Inc.
Earlier in the year, Chief Technology Officer Benjamin Machinas Beneski sold 2,867 shares at $2.50 on March 31, 2026, for a total of $7,168. Officer Annie Yoshiyama sold 9,586 shares at $2.31 on April 21, 2026, valued at $22,144. Stephen Mayo purchased 144,400 shares on June 18, 2026. General Counsel Earl Martin Douglas sold 29,697 shares at $2.12 on August 21, 2026, for a total of $62,958.
Analysts Set New Price Targets
On August 17, 2026, Citizens reiterated its market outperform rating on Allogene Therapeutics with a price target of $6.00. The stock carries a consensus recommendation key and a mean price target of $9.00 across nine analyst opinions.
About Allogene Therapeutics
Allogene Therapeutics, Inc. develops genetically engineered cell therapies for cancer and autoimmune diseases. The South San Francisco-based firm works on allogeneic CAR T cell product candidates using advanced manufacturing technologies.
Bottom Line
The CFO's recent sale offers a look at executive transactions ahead of the company's upcoming earnings report on November 5, 2026. Market watchers will track institutional filings and clinical updates for further direction.
Related Filing Alerts
Source: Geoffrey M. Parker's Form 4 filing on $ALLO (Oct 21, 2026). Written by software, not financial advice. How we make alerts